Answers are grounded in this paper and cite their sources.
Over the last twenty years, major advances have been achieved in the management of patients diagnosed with an isocitrate dehydrogenase (IDH)-mutated grade 2 glioma. Two randomized trials provided important data. First, long-term survival was demonstrated to be significantly improved (13.3 versus 7.8 years) by adding chemotherapy (procarbazine—CCNU–vincristine) to radiation therapy.1 Second, the short-term progression free survival was found to be much longer in the arm treated by vorasidenib (a new well-tolerated drug targeting IDH-mutation) rather than placebo.
No takes yet. Share an insight, caveat, or question.
Emmanuel Mandonnet (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: